1073968-65-6

Basic information

• Product Name: 5-Methoxy-1,2,3,4-tetrahydroquinoline hydrochloride
• CAS NO: 1073968-65-6
• Molecular Formula: C10H14ClNO
• Molecular Weight: 199.67726
• Mol File: 1073968-65-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-Methoxy-1,2,3,4-tetrahydroquinoline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxy-1,2,3,4-tetrahydroquinoline hydrochloride(1073968-65-6)
• EPA Substance Registry System: 5-Methoxy-1,2,3,4-tetrahydroquinoline hydrochloride(1073968-65-6)

Safety Data

• Hazardous Substances Data: 1073968-65-6(Hazardous Substances Data)

Usage

General Description

5-Methoxy-1,2,3,4-tetrahydroquinoline hydrochloride, also known as 5-MeO-THQ, is a chemical compound that belongs to the class of quinolines. It is an analogue of the hallucinogenic compound 5-methoxy-DMT, and has been shown to possess psychoactive properties. 5-MeO-THQ acts as a potent agonist at the serotonin receptors in the brain, leading to altered perception, mood and cognition. Due to its psychoactive effects, 5-MeO-THQ is used in research settings to study the mechanisms of serotonin receptor activation and its potential therapeutic applications in the treatment of various mental health disorders. However,

Upstream product

• 6931-19-7 5-methoxyquinoline 

Relevant articles and documents

Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851

We have previously reported on antitussive effect of (5R,9R,13S,14S)-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5′,6′-dihydro-3-methoxy-4′H-pyrrolo[3,2,1-ij]quinolino[2′,1′:6,7]morphinan-14-ol(1b) methanesulfonate (TRK-850), a selective δ opioid receptor antagonist which markedly reduced the number of coughs in a rat cough model. We designed TRK-850 based on naltrindole (NTI), a typical δ opioid receptor antagonist, to improve its permeability through the blood-brain barrier by introducing hydrophobic moieties to NTI. The ED50 values of NTI and compound 1b by intraperitoneal injections were 104 μg/kg and 2.07 μg/kg, respectively. This increased antitussive potency probably resulted from the improved brain exposure of compound 1b. However, 1b was extremely unstable toward metabolism by cytochrome P450. In this study, we designed and synthesized compound 1b derivatives to improve the metabolic instability, which resulted in affording highly potent and metabolically stable oral antitussive agent (5R,9R,13S,14S)-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-8′-fluoro-5′,6′-dihydro-4′H-pyrrolo[3,2,1-ij]quinolino[2′,1′:6,7]morphinan-3,14-diol (1c) methanesulfonate (TRK-851).